10x Genomics (TXG) Tops Q4 EPS by 14c

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.15), $0.14 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $156.2 million versus the consensus estimate of $148.06 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Micron Technology (MU) PT Raised to $1,280 at Baird
• Barclays Downgrades Brown Forman (BF-B) to Equalweight